首页> 外文OA文献 >Aspects of Fluorescence diagnostics and photodynamic therapy of non-melanoma skin cancer
【2h】

Aspects of Fluorescence diagnostics and photodynamic therapy of non-melanoma skin cancer

机译:非黑素瘤皮肤癌的荧光诊断和光动力疗法的方面

摘要

Aspects of fluorescence diagnostics and photodynamic therapy in non-melanoma skin cancer.Carin SandbergDepartment of Dermatology and Venereology, Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ABSTRACTPhotodynamic therapy (PDT) is now an established method to treat superficial basal cell carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). The main advantage of PDT is that it is non-invasive and gives excellent cosmetic results; although the majority of the patients do experience some degree of pain, which can sometimes be extreme. Fluorescence diagnostics (FD) is a method to diagnose mainly BCC, which is the most common type of tumour within the class of non-melanoma skin cancer (NMSC) and accounts for about 80% of all skin tumours. This technique can be used as an in vivo pre-surgical diagnostic tool, which can help to detect occult tumour borders of ill-defined BCCs. In the first study (Paper I), the impact of fluence rate and spectral range on the primary treatment outcome and bleaching rate in AKs using aminolaevulinic acid (ALA)-PDT was studied. Pain during treatment was also registered. The results imply that the photobleaching rate and primary treatment outcome were dependent on the fluence rate and that a low fluence rate (30 mW/cm2) appears preferable. In the second study (Paper II), risk factors related to pain during PDT for AK were investigated. The most important factors relating to the experience of pain seem to be the size and “redness” of the lesion. No significant pain relief with capsaicin was seen. In the third study (Paper III), the transdermal penetration of ALA and methyl-aminolaevulinate (MAL) in vivo were investigated using a microdialysis technique. The results imply that there is no significant difference in transdermal penetration of ALA and MAL in tumour tissue. Detectable levels of the drug were not obtained in almost 50% of the lesions where catheters were inserted 1-1.9 mm into the lesion. Curettage was not found to affect the interstitial concentration, indicating that penetration of the drug might indeed be a problem when treating BCCs thicker than 1 mm. In the final study presented within this thesis (Paper IV), the fluorescence contrast in patients undergoing MAL-PDT for superficial BCCs was evaluated. The MAL fluorescence contrast obtained between the tumour and normal skin was also compared to that obtained in a previous study using ALA. In both cases it was possible to identify areas in the fluorescence images corresponding to a tumour and to surrounding normal skin. The mean fluorescence contrast with MAL, however, was significantly higher than the mean fluorescence contrast after application of ALA. Thus, MAL generally renders a higher tumour contrast compared to ALA in superficial BCCs. No correlation between fluorescence and treatment response could be observed. The results of this thesis prove that PDT, using either ALA or MAL, is effective in the treatment of thin non-melanoma skin cancer and pre-cancer. These results further suggest that lower fluence rate should be considered as a precaution to minimise pain response when treating large and inflammatory lesions, although more study is needed. When performing FD, MAL is the best option and lack of treatment response cannot be connected to fluorescence but maybe due to the fact that the pro-drug does not successfully penetrate into the deeper parts of the tumour.Key words: actinic keratosis, aminolaevulinic acid, fluorescence contrast, methyl-aminolaevulinic acid, microdialysis, non-melanoma skin cancer, pain, photodynamic therapy ISBN 978-91-628-7874-0, http://hdl.handle.net/2077/21192Gothenburg 2009
机译:非黑色素瘤皮肤癌的荧光诊断和光动力疗法方面。卡林·桑德伯格(Carin Sandberg),瑞典哥德堡大学萨尔格伦斯卡学院临床科学研究所皮肤病学和性病学系。摘要光动力疗法(PDT)现在已成为治疗浅表基底细胞癌(BCC),鲍文氏病(BD)和光化性角化病(AK)的公认方法。 PDT的主要优点是它是非侵入性的,并具有出色的美容效果。尽管大多数患者的确会感到某种程度的疼痛,有时甚至是极端的。荧光诊断(FD)是主要诊断BCC的方法,BCC是非黑素瘤皮肤癌(NMSC)类中最常见的一种肿瘤,约占所有皮肤肿瘤的80%。该技术可用作体内的术前诊断工具,可帮助检测不确定的BCC的隐匿性肿瘤边界。在第一个研究(论文I)中,研究了使用氨基甲酰戊二酸(ALA)-PDT的通量率和光谱范围对AKs初级治疗结果和漂白率的影响。还记录了治疗期间的疼痛。结果暗示光漂白速率和初级处理结果取决于通量率,并且低通量率(30mW / cm 2)似乎是优选的。在第二项研究(论文II)中,研究了与AK的PDT期间疼痛相关的危险因素。与疼痛经历有关的最重要因素似乎是病变的大小和“发红”。辣椒素未见明显的止痛作用。在第三项研究(论文III)中,使用微透析技术研究了ALA和甲基氨基乙酰丙酸甲酯(MAL)在体内的透皮渗透性。结果暗示在肿瘤组织中ALA和MAL的透皮渗透没有显着差异。在将导管插入1-1.9 mm的病变中,几乎有50%的病变中未获得可检测的药物水平。未发现刮除会影响间质浓度,表明当治疗厚度大于1毫米的BCC时,药物的渗透确实可能是一个问题。在本论文提出的最终研究中(论文IV),评估了接受MAL-PDT治疗的浅表BCC患者的荧光对比。还比较了在肿瘤和正常皮肤之间获得的MAL荧光对比与先前使用ALA研究获得的对比。在这两种情况下,都可以在荧光图像中识别出对应于肿瘤和周围正常皮肤的区域。但是,与MAL的平均荧光对比明显高于应用ALA后的平均荧光对比。因此,与浅表BCC中的ALA相比,MAL通常可提供更高的肿瘤对比。荧光和治疗反应之间没有相关性。本文的结果证明,使用ALA或MAL的PDT可有效治疗薄型非黑色素瘤皮肤癌和癌前病变。这些结果进一步表明,尽管需要更多的研究,但在治疗大的和炎性病变时应将较低的注量率作为减少疼痛反应的预防措施。进行FD时,MAL是最好的选择,缺乏治疗反应不能与荧光联系起来,但这可能是由于前药不能成功渗透到肿瘤的更深部分这一事实。关键词:光化性角化病,氨基油酸,荧光造影剂,甲基氨基乙酰丙酸,微透析,非黑色素瘤皮肤癌,疼痛,光动力疗法ISBN 978-91-628-7874-0,http://hdl.handle.net/2077/21192哥德堡2009

著录项

  • 作者

    Sandberg Carin;

  • 作者单位
  • 年度 2009
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号